A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Trial Profile

A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Lefitolimod (Primary) ; Ipilimumab
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jul 2016 According to a Mologen media release, patient recruitment in this trial is expected to be completed at the beginning of 2018.
    • 13 Jul 2016 According to a Mologen media release, first patient has been enrolled in this trial.
    • 11 May 2016 Planned primary completion date changed from 1 Aug 2019 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top